Pyxis Oncology, Inc. (PYXS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7473241013
Pyxis Oncology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 13.86 m USD |
| Gross profit | 11.47 m USD |
| Operating income | -84.42 m USD |
| EBIT | -78.89 m USD |
| Net income | -79.62 m USD |
| Diluted EPS – continuing operations | -1.28 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
More stocks
- Stellus Capital Investment Corp (SCM)
- CyberTAN Technology Inc (3062.TW)
- Maeil Dairies Co. Ltd (267980.KQ)
- TSS, Inc. (TSSI)
- Eaton Vance Municipal Income Term Closed Fund (ETX)
- Waffer Technology Corp (6235.TW)
- Syscom Computer Engineering Co (2453.TW)
- Universal Microelectronics Co Ltd (2413.TW)
- Vente Unique.com (ALVU.PA)
- Daemyoung Energy Co Ltd (389260.KQ)
- Jasuindo Tiga Perkasa Tbk (JTPE.JK)
- Taigen Biopharmaceuticals Holdings Ltd (4157.TWO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.